U.S., Sept. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07151690) titled 'BCMA/CD3 Bispecific Antibody Treatment for Newly Diagnosed Amyloidosis' on Aug. 04.
Brief Summary: This is a prospective, single-arm, single-center clinical study designed to evaluate the efficacy and safety of low-dose BCMA/CD3 bispecific antibody (CM336) in patients newly diagnosed with systemic light chain (AL) amyloidosis.
Study Start Date: Aug. 27
Study Type: INTERVENTIONAL
Condition:
Systemic Light Chain Amyloidosis
Intervention:
DRUG: anti-BCMA/CD3 bispecific antibody
CM336 is a bispecific T-cell engager targeting B-cell maturation antigen (BCMA) and CD3. In this study, CM336 is administered subcutaneously with a step-...